Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Erythropoietin on Platelet Activation Markers
NCT01392612Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Nov 2006
- Primary completion
- Feb 2007
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of epoetin alfa in anemia, sponsored by Medical University of Vienna. Primary endpoint: Change in platelet activation markers at 72 hours. Started Nov 2006; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT01392612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01392612.